Fig. 1From: Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case reportThe preoperative change of the patient’s serum AFP, LDH, and NLR from October 10, 2020, to April 14, 2021. AFP, alpha-fetoprotein; LDH, lactate dehydrogenase; NLR, ratio of neutrophils to lymphocytesBack to article page